Study Looking at Reducing Side Effects of Investigational Drug in Patients with Lung Cancer

What we are studying

Researchers want to study the side effects of an investigational drug when treating non-small cell lung cancer (NSCLC). In addition to looking at the safety of this drug, this study will explore whether taking prophylactic medication (an oral antibiotic, a topical steroid, probiotic), or stopping the drug for a brief period of time, will minimize specific skin and GI side effects and improve the quality of life in patients.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosed with advanced non-small cell lung cancer (NSCLC)
  • Disease has progressed or subject is intolerant to therapy received due to toxicity

What is involved

  • 1 screening visit
  • Treatment period is divided into 4 week cycles (28 days)
  • Subjects can stay on the study and continue to receive the study drug to treat their lung cancer until their cancer gets worse; an unacceptable side effect is seen; or the subject decides to stop taking treatment



Contact Information

Study Coordinator
Scarlett Hutchens

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.